{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ventilator+Associated+Bacterial+Pneumonia+%28VABP%29",
    "query": {
      "condition": "Ventilator Associated Bacterial Pneumonia (VABP)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 13,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ventilator+Associated+Bacterial+Pneumonia+%28VABP%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T04:54:33.761Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02288234",
      "title": "Telavancin Observational Use Registry (TOUR)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hospital Acquired Bacterial Pneumonia",
        "Complicated Skin and Skin Structure Infections",
        "Ventilator Associated Bacterial Pneumonia",
        "Gram Positive Infection"
      ],
      "interventions": [
        {
          "name": "Vibativ",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cumberland Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1063,
      "start_date": "2014-11",
      "completion_date": "2017-10",
      "has_results": false,
      "last_update_posted_date": "2019-01-15",
      "last_synced_at": "2026-10-09T04:54:33.761Z",
      "location_count": 1,
      "location_summary": "Southfield, Michigan",
      "locations": [
        {
          "city": "Southfield",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02288234"
    },
    {
      "nct_id": "NCT02168946",
      "title": "Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Urinary Tract Infection Complicated",
        "Acute Pyelonephritis",
        "Hospital Acquired Bacterial Pneumonia",
        "Ventilator-associated Bacterial Pneumonia",
        "Bacteremia",
        "Abdominal Infection"
      ],
      "interventions": [
        {
          "name": "Vabomere",
          "type": "DRUG"
        },
        {
          "name": "Best Available Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 77,
      "start_date": "2014-07",
      "completion_date": "2017-07-21",
      "has_results": true,
      "last_update_posted_date": "2019-03-04",
      "last_synced_at": "2026-10-09T04:54:33.761Z",
      "location_count": 20,
      "location_summary": "Hartford, Connecticut • Tampa, Florida • Augusta, Georgia + 16 more",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02168946"
    },
    {
      "nct_id": "NCT03894046",
      "title": "Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acinetobacter Baumannii-calcoaceticus Complex",
        "Hospital-acquired Bacterial Pneumonia",
        "Ventilator-associated Bacterial Pneumonia",
        "Bacteremia",
        "Colistin Resistant ABC"
      ],
      "interventions": [
        {
          "name": "Sulbactam",
          "type": "DRUG"
        },
        {
          "name": "Durlobactam",
          "type": "DRUG"
        },
        {
          "name": "Colistin",
          "type": "DRUG"
        },
        {
          "name": "Imipenem/Cilastatin 500 mg/500 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Entasis Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 207,
      "start_date": "2019-09-05",
      "completion_date": "2021-07-26",
      "has_results": true,
      "last_update_posted_date": "2023-02-01",
      "last_synced_at": "2026-10-09T04:54:33.761Z",
      "location_count": 5,
      "location_summary": "Chicago, Illinois • Shreveport, Louisiana • Cincinnati, Ohio + 2 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03894046"
    },
    {
      "nct_id": "NCT03409679",
      "title": "Pivotal Study in VAP Suspected or Confirmed to be Due to Pseudomonas Aeruginosa",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pneumonia"
      ],
      "interventions": [
        {
          "name": "Murepavadin",
          "type": "DRUG"
        },
        {
          "name": "Two anti-pseudomonal antibiotics",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Polyphor Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2018-03-23",
      "completion_date": "2019-07-17",
      "has_results": false,
      "last_update_posted_date": "2019-08-28",
      "last_synced_at": "2026-10-09T04:54:33.761Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Springfield, Missouri • Greensboro, North Carolina",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Springfield",
          "state": "Missouri"
        },
        {
          "city": "Greensboro",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03409679"
    },
    {
      "nct_id": "NCT02420366",
      "title": "Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Urinary Tract Infection, Complicated",
        "Acute Pyelonephritis",
        "Hospital Acquired Bacterial Pneumonia",
        "Ventilator-associated Bacterial Pneumonia",
        "Bacteremia"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 257,
      "start_date": "2014-05",
      "completion_date": "2015-01",
      "has_results": false,
      "last_update_posted_date": "2018-05-02",
      "last_synced_at": "2026-10-09T04:54:33.761Z",
      "location_count": 12,
      "location_summary": "Chicago, Illinois • Evanston, Illinois • Detroit, Michigan + 8 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Somers Point",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02420366"
    },
    {
      "nct_id": "NCT06801223",
      "title": "A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)"
      ],
      "interventions": [
        {
          "name": "Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours)",
          "type": "DRUG"
        },
        {
          "name": "Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours)",
          "type": "DRUG"
        },
        {
          "name": "Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours)",
          "type": "DRUG"
        },
        {
          "name": "Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 12 hours)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Innoviva Specialty Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Day",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "1 Day to 18 Years"
      },
      "enrollment_count": 48,
      "start_date": "2026-12-30",
      "completion_date": "2028-05-20",
      "has_results": false,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-10-09T04:54:33.761Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • San Diego, California • Greenville, North Carolina + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Greenville",
          "state": "North Carolina"
        },
        {
          "city": "Galveston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06801223"
    },
    {
      "nct_id": "NCT06746883",
      "title": "A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacter Baumannii-calcoaceticus (ABC) Complex Infection",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)"
      ],
      "interventions": [
        {
          "name": "Non-interventional",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Innoviva Specialty Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2025-04-28",
      "completion_date": "2029-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-24",
      "last_synced_at": "2026-10-09T04:54:33.761Z",
      "location_count": 12,
      "location_summary": "Sacramento, California • Gainesville, Florida • Tampa, Florida + 9 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06746883"
    },
    {
      "nct_id": "NCT05204563",
      "title": "Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia"
      ],
      "interventions": [
        {
          "name": "Combination of Imipenem/Cilastatin and XNW4107",
          "type": "DRUG"
        },
        {
          "name": "Imipenem/Cilastatin/Relebactam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Evopoint Biosciences Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 450,
      "start_date": "2022-07-31",
      "completion_date": "2024-09-29",
      "has_results": true,
      "last_update_posted_date": "2025-11-06",
      "last_synced_at": "2026-10-09T04:54:33.761Z",
      "location_count": 10,
      "location_summary": "Denver, Colorado • Hartford, Connecticut • Miami, Florida + 7 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05204563"
    },
    {
      "nct_id": "NCT01570192",
      "title": "Clinical Trials to Reduce the Risk of Antimicrobial Resistance",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bacterial Pneumonia"
      ],
      "interventions": [
        {
          "name": "IV meropenem",
          "type": "DRUG"
        },
        {
          "name": "I.V. Meropenem",
          "type": "DRUG"
        },
        {
          "name": "Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h",
          "type": "DRUG"
        },
        {
          "name": "Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage.",
          "type": "DRUG"
        },
        {
          "name": "tobramycin nebulization",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2010-09",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2017-09-29",
      "last_synced_at": "2026-10-09T04:54:33.761Z",
      "location_count": 8,
      "location_summary": "San Mateo, California • Gainesville, Florida • Atlanta, Georgia + 5 more",
      "locations": [
        {
          "city": "San Mateo",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "North Liberty",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01570192"
    },
    {
      "nct_id": "NCT03032380",
      "title": "Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Healthcare-associated Pneumonia (HCAP)",
        "Hospital Acquired Pneumonia (HAP)",
        "Ventilator Associated Pneumonia (VAP)"
      ],
      "interventions": [
        {
          "name": "Cefiderocol",
          "type": "DRUG"
        },
        {
          "name": "Meropenem",
          "type": "DRUG"
        },
        {
          "name": "Linezolid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shionogi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2017-10-24",
      "completion_date": "2019-04-01",
      "has_results": true,
      "last_update_posted_date": "2020-11-13",
      "last_synced_at": "2026-10-09T04:54:33.761Z",
      "location_count": 15,
      "location_summary": "New Haven, Connecticut • DeLand, Florida • Chicago, Illinois + 12 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Council Bluffs",
          "state": "Iowa"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03032380"
    }
  ]
}